The study population was chosen from a non-probability sample.
The safety population consisted of all participants with at least one documented infusion of infliximab.
The evaluable population consisted of all participants that were \>=18 years of age with a recorded indication for infliximab use, that had available baseline data, and with at least 3 infusions of infliximab within the first 16 weeks of the study. Baseline characteristics are provided for this population.
